SG Americas Securities LLC Boosts Stock Position in DexCom, Inc. $DXCM

SG Americas Securities LLC boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 271.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,065,277 shares of the medical device company’s stock after purchasing an additional 1,509,219 shares during the quarter. SG Americas Securities LLC’s holdings in DexCom were worth $129,699,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Trust Co. of Vermont boosted its holdings in shares of DexCom by 14.8% in the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after buying an additional 145 shares in the last quarter. CVA Family Office LLC raised its stake in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares in the last quarter. IFP Advisors Inc raised its stake in shares of DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after acquiring an additional 178 shares in the last quarter. Personal CFO Solutions LLC lifted its position in DexCom by 5.0% during the third quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock valued at $260,000 after acquiring an additional 185 shares during the last quarter. Finally, Keel Point LLC lifted its position in DexCom by 3.1% during the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock valued at $430,000 after acquiring an additional 193 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In related news, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the transaction, the director owned 25,007 shares in the company, valued at $1,500,670.07. This trade represents a 3.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the sale, the director directly owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 46,694 shares of company stock valued at $3,343,977. Company insiders own 0.28% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on DXCM shares. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Citigroup reaffirmed a “buy” rating and set a $84.00 price target (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. UBS Group set a $95.00 price objective on DexCom in a report on Wednesday, June 10th. Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective for the company in a research report on Tuesday, March 24th. Finally, Benchmark initiated coverage on DexCom in a research note on Monday, May 11th. They set a “buy” rating and a $77.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $84.83.

DexCom Stock Performance

Shares of DexCom stock opened at $72.47 on Monday. The company has a 50 day moving average price of $67.07 and a 200 day moving average price of $67.95. The firm has a market capitalization of $27.96 billion, a P/E ratio of 30.97, a PEG ratio of 1.13 and a beta of 1.45. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the firm earned $0.32 EPS. DexCom’s revenue was up 15.0% compared to the same quarter last year. Sell-side analysts expect that DexCom, Inc. will post 2.58 EPS for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.